01 Growth of Ophthalmology Clinics as Key End-Users for Premium Ophthalmic Viscosurgical Devices Ophthalmology clinics are emerging as major end-users of premium ophthalmic viscosurgical devices (OVDs), driven by the increasing number of solo ophthalmology practices. These clinics are adopting advanced OVDs to enhance surgical precision and improve patient outcomes, particularly in premium intraocular lens (IOL) implantation. According to the American Academy of Ophthalmology, as of 2022, there were approximately 18,000 practicing ophthalmologists in the U.S., with nearly 26% operating independently in solo practices. This rise in independent clinics reflects the growing demand for specialized, high-quality ophthalmic care, further fueling the adoption of advanced OVDs.
April 2026 Alcon strengthened its cataract surgery portfolio by enhancing ophthalmic viscosurgical devices with improved cohesive and dispersive properties to support safer and more efficient intraocular procedures.
February 2026 Bausch + Lomb expanded its ophthalmic surgery portfolio by launching advanced OVD solutions engineered to improve endothelial protection and optimize surgical outcomes in cataract and anterior segment surgeries.
September 2025 Carl Zeiss Meditec expanded its ophthalmic surgical ecosystem through enhanced integration of OVD-compatible technologies with advanced cataract surgery platforms, improving procedural workflow and precision.
May 2025 Rayner strengthened its ophthalmic product portfolio by expanding solutions supporting cataract surgery, including advanced ophthalmic viscosurgical devices designed to enhance intraoperative performance and patient outcomes.